Sponsors
Blog
Where our team of editors discuss what they think about the current NGP US Issues.
Editor NGP Europe
Tough competition
The battle between generics and branded products has been going on for a long time: the claims and counter claims over Aspirin, for example, have been in process since the early 20th century.06 Aug 2009
White Papers
Focus Area: Drug Discovery
European pharma: where next?
What does Europe have to gain from an innovative, research-based pharmaceutical industry? And what challenges is the industry facing? By Brian Ager, Director General of the European Federation of Pharmaceutical Industries and Associations EFPIA.
It’s all about… Innovation
In their quest to be innovative, pharmaceutical and biotechnological companies are applying their own strategies in response to the growing demands for improvement, creative ideas, breakthrough technologies and new medicines.
The EU and you
Martin Terberger, Head of Unit, Pharmaceuticals, Directorate General, Enterprise and Industry outlines the European Commission’s view on pharma moving forward.
Great expectations
The pharmaceutical business – once the envy of fellow industries for its year-on-year surging profits – has suddenly found itself staring at a crisis.
GFC Transfection Arrays™ for High-throughput Over-expression Screening for Functional Genes in a Biological Process
Introduction
GFC Transfection Arrays are a novel screening tool to identify key functional genes in a biological pathway.
Source: www.ngpharma.eu.com© 2010 GDS Publishing Ltd. All rights reserved.